Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory ... | Region

First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

Related Keywords

Canada ,Australia ,California ,United States ,Brisbane ,Queensland ,Laura Cooper ,Sabine Mueller ,Jeremy Bender ,Courtney Davies ,Samuel Blackman ,Drug Administration ,Company On Linkedin ,European Commission ,Pediatric Brain Tumor Foundation ,Exchange Commission ,Head Of Communications ,Day One Biopharmaceuticals Inc ,Nasdaq ,Society For Neuro ,Oncology Consortium ,One Biopharmaceuticals ,Day One ,California San Francisco Benioff Children ,Response Assessment ,Pediatric Neuro Oncology Low Grade Glioma ,Pediatric Brain Tumor ,Everyday Support From Day One ,Day One Investors ,Breakthrough Therapy ,Rare Pediatric Disease ,Orphan Drug ,Product Information ,Pacific Pediatric Neuro Oncology Consortium ,Neuro Oncology High Grade Glioma ,Neuro Oncology Low Grade Glioma ,Pacific Pediatric Neuro Oncology ,Private Securities Litigation Reform Act ,Sci Advisors ,Region ,